The conference’s day three agenda shifts attention toward areas of the microbiome market that continue to gain traction with brands, suppliers and researchers alike, particularly women’s health and condition-specific formulations backed by clinical evidence.
Sessions throughout the morning are expected to examine how companies are navigating the growing demand for science-backed products while also addressing formulation, delivery and adoption challenges.
Women’s health microbiome science in the spotlight
The morning schedule is set to begin with a dedicated session focused on women’s health, an area organizers noted still presents significant gaps in scientific understanding and product development opportunities. Topics on the agenda include hormone health, menopause, menstrual issues, conception, pregnancy and vaginal health.
Caroline Carralero, founder and CEO of Daily Nouri, is scheduled to open the session with a fireside chat exploring the connection between the gut microbiome and hormone regulation across different stages of life.
The conversation is also expected to address the role clinical validation may play as women’s health products continue to move further into the mainstream supplement market.
Following the fireside chat, Dr. George Zhou, director of applied technology and global marketing manager at WeCare Probiotics, will discuss how probiotics targeting women’s health are being developed for practical, scalable applications.
His presentation will examine how companies are balancing clinical efficacy with manufacturability while also considering delivery formats designed to support convenience and consumer compliance.
The session will close with a panel discussion that considers the gap between clinically validated probiotic science and real-world adoption. Maura MacDonald, medical education specialist at Thorne will be joined by Jordi Riera, chief business officer at Kaneka Probiotics and Dr. Aouatef Bellamine, global scientific marketing director at ADM are expected to discuss formulation hurdles, communication challenges and practitioner engagement in the women’s health category.
Innovation session to examine whitespace opportunities
The conference’s second session, ‘Innovation in Action,’ turns toward emerging opportunities across the microbiome sector, including novel probiotics, prebiotics, postbiotics and delivery technologies.
Jacqueline Jacques, president of Thrive Advisory Group, will discuss how consumer perceptions around biotic ingredients are evolving and where those ingredients fit within the broader functional health landscape.
The session will also examine how companies are approaching innovation and premium positioning as competition across the category intensifies.
Afif Ghannoum, founder and CEO of CPG Radar, is then expected to present market data highlighting where probiotic demand is expanding beyond digestive health.
Areas expected to be highlighted include women’s health, prenatal supplements, sleep, mood, sports nutrition, joint health and metabolic health as companies continue to push into more targeted applications for probiotics.
Final discussion to look ahead at microbiome market trends
The event will wrap up with a quick-fire panel discussion focused on the issues expected to shape the microbiome sector over the next 12 months.
The closing discussion will feature Stephen Daniells, Editor-in-Chief of NutraIngredients, George Paraskevakos, executive director of the International Probiotics Association, and Ghannoum.
Probiota Americas 2026 will conclude with closing remarks and a networking lunch.
For more information and to register, please click here.
